GlassScriptPhysician profile
Omotayo Y Sofela
NPI 1033867007
$1,035.48
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,020 · 2024: $15.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $209.31 | 2023 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $153.81 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $130.20 | 2023 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $95.30 | 2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $94.86 | 2023 | Austedo, Austedo Xr |
| Corium, LLC | $82.23 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $61.09 | 2023 | Hetlioz, Fanapt |
| Abbvie INC. | $52.08 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.17 | 2023 | |
| Neos Therapeutics, LP | $36.41 | 2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $33.41 | 2023 | Dyanavel Xr |
| Indivior INC. | $21.36 | 2023 | Perseris |
| Alkermes, INC. | $19.25 | 2023 | Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omotayo Sofela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.